CU24546B1 - Composición vacunal que comprende un mutante de la interleucina-15 humana - Google Patents
Composición vacunal que comprende un mutante de la interleucina-15 humanaInfo
- Publication number
- CU24546B1 CU24546B1 CU2016000194A CU20160194A CU24546B1 CU 24546 B1 CU24546 B1 CU 24546B1 CU 2016000194 A CU2016000194 A CU 2016000194A CU 20160194 A CU20160194 A CU 20160194A CU 24546 B1 CU24546 B1 CU 24546B1
- Authority
- CU
- Cuba
- Prior art keywords
- human interleukin
- mutant
- composition including
- vaccinal composition
- composition
- Prior art date
Links
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 title abstract 2
- 102000056003 human IL15 Human genes 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 102000003812 Interleukin-15 Human genes 0.000 abstract 1
- 108090000172 Interleukin-15 Proteins 0.000 abstract 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Se describe una composición vacunal caracterizada porque comprende un polipéptido mutado de interleucina-15 humana identificado como SEQ ID NO: 1 en una concentración de 200-500 µg y un adyuvante vacunal, seleccionado de sales de aluminio a 1,8 mg/mL o de tipo oleoso en una relación 50:50 (v/v). La composición se emplea para la inmunoterapia activa de enfermedades relacionadas con la sobre-expresión de la IL-15 entre las que se encuentran algunas enfermedades autoinmunes y neoplasias hematológicas.</p>
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| CN201780086587.4A CN110300762B (zh) | 2016-12-30 | 2017-12-20 | 包含人白介素-15的突变体的疫苗组合物 |
| US16/474,913 US20200181254A1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
| EP17840472.9A EP3564264B1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
| PCT/CU2017/050008 WO2018121802A1 (es) | 2016-12-30 | 2017-12-20 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| MX2019007906A MX2019007906A (es) | 2016-12-30 | 2017-12-20 | Composicion vacunal que comprende un mutante de la interleucina-15 humana. |
| ES17840472T ES2892148T3 (es) | 2016-12-30 | 2017-12-20 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| BR112019013542A BR112019013542A2 (pt) | 2016-12-30 | 2017-12-20 | composição de vacina, uso de um polipeptídeo, e, método para o tratamento de doenças associadas à superexpressão da il-15 |
| RU2019122635A RU2745199C2 (ru) | 2016-12-30 | 2017-12-20 | Вакцинная композиция, содержащая мутантный человеческий интерлейкин-15 |
| US17/531,914 US20220259300A1 (en) | 2016-12-30 | 2021-11-22 | Vaccine composition comprising a mutant of human interleukin-15 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160194A7 CU20160194A7 (es) | 2018-08-06 |
| CU24546B1 true CU24546B1 (es) | 2021-09-07 |
Family
ID=61188581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200181254A1 (es) |
| EP (1) | EP3564264B1 (es) |
| CN (1) | CN110300762B (es) |
| BR (1) | BR112019013542A2 (es) |
| CU (1) | CU24546B1 (es) |
| ES (1) | ES2892148T3 (es) |
| MX (1) | MX2019007906A (es) |
| RU (1) | RU2745199C2 (es) |
| WO (1) | WO2018121802A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179066A1 (en) * | 2020-05-18 | 2021-11-25 | Jing DENG | Human il-15 mutant and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| ATE298367T1 (de) | 1996-04-26 | 2005-07-15 | Beth Israel Hospital | Interleukin-15 antagoniste |
| CU23093A1 (es) * | 2002-10-09 | 2005-10-19 | Ct Ingenieria Genetica Biotech | Composición vacunal que comprende interleucina-15 (il-15) |
| NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| ATE516305T1 (de) * | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
| US20060057102A1 (en) * | 2004-08-11 | 2006-03-16 | Zheng Xin X | Mutant interleukin-15-containing compositions and suppression of an immune response |
| NZ555590A (en) * | 2004-12-13 | 2009-07-31 | Cytos Biotechnology Ag | Compositions comprising a VLP and IL-15 protein |
| CU23716A1 (es) * | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
| CA3102821A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
-
2016
- 2016-12-30 CU CU2016000194A patent/CU24546B1/es unknown
-
2017
- 2017-12-20 CN CN201780086587.4A patent/CN110300762B/zh active Active
- 2017-12-20 MX MX2019007906A patent/MX2019007906A/es unknown
- 2017-12-20 WO PCT/CU2017/050008 patent/WO2018121802A1/es unknown
- 2017-12-20 EP EP17840472.9A patent/EP3564264B1/en active Active
- 2017-12-20 RU RU2019122635A patent/RU2745199C2/ru active
- 2017-12-20 BR BR112019013542A patent/BR112019013542A2/pt unknown
- 2017-12-20 ES ES17840472T patent/ES2892148T3/es active Active
- 2017-12-20 US US16/474,913 patent/US20200181254A1/en not_active Abandoned
-
2021
- 2021-11-22 US US17/531,914 patent/US20220259300A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2892148T3 (es) | 2022-02-02 |
| EP3564264A1 (en) | 2019-11-06 |
| MX2019007906A (es) | 2019-09-04 |
| EP3564264B1 (en) | 2021-09-08 |
| RU2745199C2 (ru) | 2021-03-22 |
| RU2019122635A3 (es) | 2021-02-01 |
| US20200181254A1 (en) | 2020-06-11 |
| CN110300762B (zh) | 2023-05-02 |
| CN110300762A (zh) | 2019-10-01 |
| CU20160194A7 (es) | 2018-08-06 |
| US20220259300A1 (en) | 2022-08-18 |
| WO2018121802A1 (es) | 2018-07-05 |
| BR112019013542A2 (pt) | 2020-02-04 |
| RU2019122635A (ru) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CO2018009068A2 (es) | Derivados de indol y azaindol haloalilamina como inhibidores de lisil oxidasas y usos de los mismos | |
| EA201791717A1 (ru) | Стабильные водные составы адалимумаба | |
| NZ737046A (en) | Anti-cgrp antibody formulation | |
| CY1124076T1 (el) | Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος | |
| PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
| EA201790294A1 (ru) | Средства на основе флагеллина и применения, включающие эффективную вакцинацию | |
| PE20160225A1 (es) | Modulacion de la inmunidad tumoral | |
| EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| AR074756A1 (es) | Anticuerpos contra la angiopoyetina-2 humana | |
| GT201200189A (es) | Antagonistas de pcsk9 | |
| TR201910573T4 (tr) | Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. | |
| MX2019013621A (es) | Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. | |
| PE20140173A1 (es) | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis | |
| EA201270741A1 (ru) | Пероральные композиции и липофильные соли метилналтрексона | |
| PE20131411A1 (es) | Anticuerpos contra la tweak humana y usos de los mismos | |
| CY1114716T1 (el) | Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες | |
| EA201991799A1 (ru) | Диспергируемые в воде составы | |
| MX360085B (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
| EA201390010A1 (ru) | Замещенные триазолопиридины | |
| ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| MD3341379T2 (ro) | Inhibitori ai EZH2 | |
| AR100913A1 (es) | Síntesis de complejo de zinc-lisina a partir de cloruro de zinc |